86.24 +0.90 (1.05%)
Pre-Market: 5:44AM EDT
|Bid||86.33 x 3100|
|Ask||86.39 x 900|
|Day's Range||84.73 - 85.57|
|52 Week Range||72.30 - 94.19|
|Beta (3Y Monthly)||0.86|
|PE Ratio (TTM)||14.49|
|Forward Dividend & Yield||2.98 (3.60%)|
|1y Target Est||98.50|
Novartis is paying $2.1 billion for nuclear medicine specialist Endocyte in Chief Executive Vas Narasimhan's latest deal to reshape the Swiss drugs group from a pillmaker to a producer of sophisticated therapies. Narasimhan, who raised Novartis's 2018 revenue forecast on Thursday as he released third-quarter results, is counting on Endocyte's treatment for prostate cancer topping $1 billion in sales after it hits the U.S. market in 2021. Some analysts said the deal, seen closing next year, fitted his push into high-margin specialty treatments, but was very expensive.
On a per-share basis, the Basel, Switzerland-based company said it had profit of 69 cents. Earnings, adjusted for non-recurring costs, came to $1.31 per share. The results met Wall Street expectations. ...
Novartis is paying $2.1 billion for nuclear medicine specialist Endocyte in Chief Executive Vas Narasimhan's latest deal to reshape the Swiss drugs group from a pillmaker to a producer of sophisticated therapies. Narasimhan, who raised Novartis's 2018 revenue forecast on Thursday as he released third-quarter results, is counting on Endocyte's treatment for prostate cancer topping $1 billion in sales after it hits the U.S. market in 2021. Since taking over in February, Narasimhan has shed over-the-counter medicines and generic pills while pushing a spinoff of Novartis's Alcon eyecare unit come 2019.
Thursday’s busy corporate news agenda includes a $2.1 billion U.S. acquisition by Novartis and a host of blue-chip trading updates.
0758 GMT - Carrefour’s third-quarter sales update shows improved momentum and its long list of achievements shows the new management team has hit the ground running, say analysts at Jefferies. “We note good progress in French supers post the April price reinvestment as the most tangible sign of renewed commercial traction,” says Jefferies. 0752 GMT - SAP’s 3Q results indicate its cloud business will see significant acceleration, even as the German software maker’s transition to cloud services has “mixed” implications for the share price short-term, says Jefferies.
Inc., a U.S. company developing a new treatment for prostate cancer, the Swiss pharmaceutical giant’s latest move to double down on high-value prescription drugs. Endocyte specializes in so-called radiopharmaceuticals, a new class of drug that carries radioactive substances directly to cancer cells so they can kill tumor cells at close range. The deal will add a prostate cancer radiopharmaceutical to Novartis’s late-stage pipeline, bolstering its capability in the field, which it expects to be a key growth driver for its business.
The $24-per-share offer represents a premium of 54 percent to Endocyte's Wednesday closing price. Endocyte said the deal will help develop a broader role for radioligand therapies in cancer treatment. The deal will also enable Novartis to investigate the potential development of a drug candidate for use in earlier lines of prostate cancer therapy, it said.
Novartis AG will acquire U.S.-based cancer drugmaker Endocyte Inc for $2.1 billion in cash as the Swiss drugmaker expands its radiopharmaceuticals business, the companies said on Thursday. The $24-per-share offer represents a premium of 54 percent to Endocyte's Wednesday closing price. Endocyte said the deal will help develop a broader role for radioligand therapies in cancer treatment.
By John Miller ZURICH (Reuters) - Swiss drugmaker Novartis (NOVN.S) raised its full-year sales outlook, citing growing revenue from its Cosentyx psoriasis and arthritis drug as well as the performance ...
Novartis announced on Thursday the $2.1 billion acquisition of U.S. biopharmaceutical company Endocyte. "We are very pleased with how the innovative medicines business is performing, we are seeing strong growth on our key growth drivers Entresto and Cosentyx as well as across our oncology portfolio," Vasant Narasimhan, CEO of Novartis, told CNBC's "Squawk Box Europe" on Thursday. Swiss drugmaker Novartis NOVN-CH raised its full-year sales outlook, citing growing revenue from its Cosentyx psoriasis and arthritis drug as well as the performance of its heart failure medicine Entresto, whose third-quarter sales more than doubled.
Biopharmaceutical company Endocyte Inc said on Thursday that Novartis AG will acquire Endocyte in an all-cash deal for $24 per share, or a total equity value of about $2.1 billion. The offer represents ...
Swiss drugmaker Novartis raised its full-year sales outlook on Thursday, citing growing revenue from its Cosentyx psoriasis and arthritis drug as well as the performance of its heart failure medicine Entresto, ...
Don't be caught off-guard: Novartis AG (NYSE: NVS ) releases its next round of earnings this Thursday, Oct. 18. Want to skip the homework and get all the facts in one place? We thought so. Here is your ...
is now official after U.S. District Judge Alison Nathan signed the settlement in Manhattan, Tuesday, Oct. 16. As part of the settlement, Musk will have to step down as chairman of the electric vehicle company and will have to personally pay a $20 million fine in addition to a separate $20 million fine levied against Tesla. The court action comes in the wake of a tweet Musk sent on Aug. 7, suggesting that he had secured enough funding to take the company private at $420 a share.
Shares of Tilray Inc. (NASDAQ: TLRY ) surged Monday in anticipation of Canada’s legalization of recreational marijuana. The Analyst Benchmark analyst Mike Hickey initiated coverage of Tilray with a Buy ...
The rating is based on an analysts' view that Wednesday's full legalization of cannabis in Canada will be a boon for the company.
Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal.
Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. Amgen is rolling out its so-called biosimilar form of Humira, branded as Amgevita, across Europe from Oct. 16, while Novartis said its Sandoz unit was launching its product Hyrimoz initially in Britain, with other markets set to follow. Large sums are at stake, since Humira clocked up worldwide sales of $18 billion last year, of which around $4 billion came from Europe, and European healthcare administrators are eager to exploit the competitive situation to drive down drug bills.
Shares of Tilray Inc. shot up 5.7% in premarket trade Tuesday, after Benchmark analyst Mike Hickey started coverage of the Canada-based medical cannabis and cannabinoid company with a buy rating and $200 price target. Hickey's price target is 21% above Monday's closing price $165.64. Hickey said his bullish view is based on the company's early leadership in the medical cannabis market in Canada, the upcoming full legalization of recreational marijuana in Canada and its strategic alliance with Novartis AG and supply agreements with Canadian pharmacies, international growth opportunities and a "meaningful" capital infusion from its initial public offering in July. "We believe establishing an early first mover advantage is critically important in the emerging cannabis market, particularly when it comes to building national and global scale, leading brands, and developing innovative products and form factors that use cannabis as an active ingredient," Hickey wrote in a note to clients. The stock has rocketed more than 7-fold since closing at $22.39 on its first day listed on the Nasdaq on July 19, while the ETFMG Alternative Harvest ETF has run up 55% and the S&P 500 has lost 1.9% over the same time.
just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.
Wall Street analysts estimate that Novartis (NVS) will report revenues of $13.02 billion for the third quarter of 2018, a 4.9% growth year-over-year compared to $12.41 billion. Novartis stock has decreased ~4.9% over the last 12 months. As of October 12, there are two analysts tracking Novartis ADR (American Depositary Receipts).
Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.
Novartis (NVS) is set to release its third quarter of 2018 earnings results on October 18. Analysts are estimating EPS of $1.31 and revenues of $13.02 billion. Novartis, one of the largest pharmaceutical companies by revenue, specializes in the development, manufacturing, and marketing of healthcare products.
Bausch + Lomb/International, a subsidiary of Bausch Health (BHC), generated net revenues of $1.21 billion in the second quarter, compared to $1.22 billion in the second quarter of 2017. This increase reflects ~4.0% YoY (year-over-year) organic growth.